SSA
PRME icon

Schonfeld Strategic Advisors’s Prime Medicine PRME Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-593,039
Closed -$3.29M – 2485
2025
Q3 		$3.29M Sell
593,039
-225,479
-28% -$916K 0.02% 791
2025
Q2 		$2.02M Buy
+818,518
New +$1.26M 0.01% 977
2024
Q2 		– Sell
-330,500
Closed -$2.31M – 2485
2024
Q1 		$2.31M Buy
+330,500
New +$2.51M 0.02% 941

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Schonfeld Strategic Advisors's PRME Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Prime Medicine (PRME) in Q4 2025, closing a stake of 593,039 shares — an estimated $3.29M sold.

Schonfeld Strategic Advisors first reported a position in PRME in Q1 2024 and held it in 3 quarters. The position peaked at $3.29M in Q3 2025. 183 funds tracked by Wall St. Rank hold PRME as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Prime Medicine position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 593,039 Prime Medicine shares in Q4 2025, an estimated $3.29M.
  • Schonfeld Strategic Advisors first reported a position in Prime Medicine in Q1 2024 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Prime Medicine position peaked at $3.29M in Q3 2025.
  • 183 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.